Zynteglo
Drug
bluebird bio, Inc.
Total Payments
$1.5M
Transactions
202
Doctors
96
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $679,598 | 71 | 42 |
| 2023 | $827,544 | 131 | 58 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 72 | 97.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,250 | 1 | 1.1% |
| Consulting Fee | $8,375 | 4 | 0.6% |
| Food and Beverage | $7,182 | 125 | 0.5% |
Payments by Type
Research
$1.5M
72 transactions
General
$31,807
130 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector | bluebird bio, Inc. | $756,278 | 0 |
| A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral A T87Q Globin Vector in Subjects <50 Years of Age | bluebird bio, Inc. | $680,312 | 0 |
| A Safety and Effectiveness Registry Study of Patients with β‑Thalassemia Treated with Betibeglogene Autotemcel (Glostar) | bluebird bio, Inc. | $37,420 | 0 |
| A Phase 3 Singe Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent b-Thalassemia, who do not have b 0 /b0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral b A-T87Q-Globin Vector in Subjects >12 and <50 Years of Age | bluebird bio, Inc. | $1,325 | 0 |
Top Doctors Receiving Payments for Zynteglo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Northbrook, IL | $1.5M | 73 |
| , M.D | Diagnostic Radiology | Burnsville, MN | $4,775 | 3 |
| , MD, MS | Pediatric Hematology-Oncology | La Jolla, CA | $3,600 | 1 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $399.45 | 5 |
| , M.D | Pediatric Hematology-Oncology | New Orleans, LA | $399.45 | 5 |
| , MD | Pediatrics | New Orleans, LA | $279.97 | 3 |
| , M.D | Medical Oncology | Tampa, FL | $242.87 | 2 |
| , MD | Hematology & Oncology | Atlanta, GA | $241.06 | 7 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $202.42 | 4 |
| , MD | Hematology & Oncology | Tampa, FL | $198.28 | 2 |
| , M.D | Pediatric Hematology-Oncology | New Orleans, LA | $198.20 | 2 |
| , M.D | Pediatric Hematology-Oncology | New Orleans, LA | $198.20 | 2 |
| , M.D | Pediatric Hematology-Oncology | San Antonio, TX | $171.54 | 1 |
| , M.D | Hematology & Oncology | San Antonio, TX | $171.54 | 1 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $149.64 | 2 |
| , MD | Hematology & Oncology | Gainesville, FL | $141.53 | 1 |
| , AGPCNP | Nurse Practitioner | Tampa, FL | $141.53 | 1 |
| , MD | Hematology & Oncology | Tampa, FL | $141.53 | 1 |
| , MD | Neurology | Tampa, FL | $141.53 | 1 |
| , NP | Gerontology | Boston, MA | $138.67 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Boston, MA | $138.67 | 1 |
| , MD | Internal Medicine | Boston, MA | $138.67 | 1 |
| , MD, PHD | Hematology | Boston, MA | $138.67 | 1 |
| , MD, MPH | Pediatric Hematology-Oncology | New Orleans, LA | $138.28 | 2 |
| , M.D | Pediatric Hematology-Oncology | Richmond, VA | $138.28 | 2 |
Ad
Manufacturing Companies
- bluebird bio, Inc. $1.5M
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 96
- Transactions 202
About Zynteglo
Zynteglo is a drug associated with $1.5M in payments to 96 healthcare providers, recorded across 202 transactions in the CMS Open Payments database. The primary manufacturer is bluebird bio, Inc..
Payment data is available from 2023 to 2024. In 2024, $679,598 was paid across 71 transactions to 42 doctors.
The most common payment nature for Zynteglo is "Unspecified" ($1.5M, 97.9% of total).
Zynteglo is associated with 4 research studies, including "Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector" ($756,278).